Skip to Main Content

A drug from the Dutch biotech Merus designed to disrupt a rare genetic alteration is showing early but promising anti-tumor responses in patients with advanced pancreatic cancer — a disease with few effective treatment options available.

When treated with infusions of the Merus drug, called zenocutuzumab, four of 10 patients with pancreatic cancer showed partial responses, for a confirmed overall response rate of 40%. Another three patients had minor tumor responses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED